Skip to main content

Table 1 Baseline demographic and clinicopathological characteristics

From: Up-front systemic chemotherapy is a feasible option compared to primary tumor resection followed by chemotherapy for colorectal cancer with unresectable synchronous metastases

Characteristic USC ( N= 15) PTR ( N= 42) P value
Follow-up duration (months) 13.4 (11.3 to 23.2) 19.2 (12.4 to 28.9) 0.232
Age (years) 63 (48 to 65) 61.5 (54 to 70.5) 0.568
Sex Male 7 8 0.048
  Female 8 34  
BMI (kg/m2) 21.2 (16.9 to 25.5) 21.4 (19.8 to 23.1) 0.978
Performance status 0 14 39 1.00
  1 1 3  
  ≥2 0 0  
ASA score 1 3 10 0.949
  2 11 29  
  3 1 3  
  4 0 0  
Primary tumor site Right colon 1 13 0.005
  Left colon 3 18  
  Rectum 11 11  
KRAS status Wild type 6 24 0.368
  Mutant or unknown 9 18  
CEA 23.1 (4.1 to 60.3) 41.5 (12.9 to 344) 0.074
Invasion depth T2 0 1 0.337
  T3 6 17  
  T4a 9 20  
  T4b 0 4  
Lymph node metastasis Negative 1 5 1.00
  Positive 14 37  
Sum of the longest diameters of metastases (mm) 61 (46 to 150) 75 (41.5 to 109) 0.697
Number of metastases 17 (6 to 52) 11.5 (5.5 to 28) 0.309
Number of organs with metastasis 2 (1 to 2) 2 (1 to 2) 0.899
Peritoneal dissemination 2 (13.3%) 7 (16.7%) 1.00
Total lines of chemotherapy 2 (2 to 3) 2 (1 to 3) 1.00
Use or any molecular target agents 13 (86.7%) 37 (88.1%) 1.00
Bevacizumab 12 (80.0%) 33 (78.6%) 1.00
Cetuximab and/or panitumumab* 6 (100%) 16 (66.7%) 0.155
Use of oxaliplatine combination 14 (93.3%) 36 (85.7%) 0.66
Use irinotecan combination 12 (80.0%) 26 (61.9%) 0.339
Conversion 1 (6.7%) 0 (0%) 0.263
  1. USC: up-front systemic chemotherapy group. PTR: primary tumor resection group. BMI: body mass index. ASA score: American Society of Anesthesiologists score. KRAS: Kirsten rat sarcoma viral oncogene. CEA: carcinoembryonic antigen. Variables were statistically analyzed by Wilcoxon’s rank-sum test (quantitative variables), Fisher’s exact test (categorical, binary) or Chi-square test (categorical, more than three variables). *Use of cetuximab and/or panitumumab was presented as frequency in the KRAS exon 2 wild-type tumor only.